Simponi Aria News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Serious infections were uncommon among patients with psoriatic arthritis exposed to targeted therapies for the first time in “a large and exhaustive” French cohort, according to data published in RMD Open.Compared with new users of adalimumab (Humira, Abbvie), risk for serious infection was significantly lower among new users of etanercept (Enbrel, Immunex) and ustekinumab (Stelara,

Total revenues in Q1 2024 increased to $37 million compared to $16 million in the same period last yearGross margin in Q1 2024 increased to $17 million, by $40 million compared to the same period last...

Alvotech (NYSE:ALVO – Get Free Report) is one of 289 publicly-traded companies in the “Biological products, except diagnostic” industry, but how does it contrast to its competitors? We will compare Alvotech to related companies based on the strength of its analyst recommendations, valuation, risk, profitability, dividends, institutional ownership and earnings. Insider & Institutional Ownership 50.3% […]

Alvotech (NYSE:ALVO – Get Free Report) is one of 289 publicly-traded companies in the “Biological products, except diagnostic” industry, but how does it weigh in compared to its rivals? We will compare Alvotech to related businesses based on the strength of its earnings, analyst recommendations, institutional ownership, risk, profitability, valuation and dividends. Analyst Recommendations This […]

The confirmatory clinical safety and efficacy study for AVT05, biosimilar candidate to Simponi® and Simponi Aria® , met its primary endpoint in patients with moderate to severe rheumatoid...